A new chapter in the history of medicinal cannabis may be about to begin in Europe. The German pharmaceutical company Vertanical presented promising results from a clinical study with VER-01, a drug made from the whole extract of Cannabis sativa. If approved, it could become the first authorized full-plant drug on the continent, a symbolic and scientific step towards more natural and comprehensive treatments. The information was confirmed by the Hispanic portal Canamo.Net.

An extract that preserves the plant's strength

Unlike formulas that isolate only one molecule, VER-01 brings together the full potential of the plant, cannabinoids, terpenes, and flavonoids, in a standardized extract. It is the so-called "entourage effect", where the combination of compounds acts synergistically in the body, enhancing therapeutic benefits.

The study, conducted with 820 patients with chronic lower back pain, showed that the use of the drug significantly reduced pain without showing signs of dependence or withdrawal. The result reinforces the idea that cannabis can be an effective and safer alternative to traditional analgesics, such as opioids.

Opening the way for new health policies

It is expected that the German government will evaluate national authorization by 2026. If approved, VER-01 could be recognized in other countries of the European Union, a move that could accelerate the development of more inclusive and evidence-based health policies.

More than a pharmaceutical breakthrough, the potential recognition of this drug symbolizes a paradigm shift: the appreciation of the plant in its complete form, respecting its natural complexity and healing potential.

With information from Canamo.net.